Gemcitabine alone or plus cisplatin for biliary tract cancer?

Werner Scheithauer

A randomised phase III trial comparing cisplatin plus gemcitabine with gemcitabine alone for patients with advanced biliary tract cancer has provided evidence for a new standard treatment option for these patients. The therapeutic outcome (overall survival, disease-free survival and disease control rate) was significantly better in the combination arm, with no increase in toxic effects

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.


*


UA-77507851-1